Business Context and Reporting Period
This Form 8-K Current Report was filed by 4D Molecular Therapeutics, Inc. on March 25, 2026. The filing addresses a corporate governance event under Item 5.02 regarding the appointment of a new officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The material change reported is the appointment of Kristian Humer as the Company's Principal Accounting Officer, effective immediately on March 25, 2026. Mr. Humer succeeds Ashoo Gupta, who will continue to serve as Vice President, Finance and Controller. Mr. Humer has served as the Company's Chief Financial Officer and Principal Financial Officer since November 2025.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. The document is limited to the disclosure of the officer appointment and Mr. Humer's professional background, which includes prior roles as CFO at Foghorn Therapeutics, Inc. and Viridian Therapeutics, Inc., and experience at Citigroup Global Markets Inc.
Investor Verification Checklist
- Verify the effective date of Kristian Humer's appointment as Principal Accounting Officer (March 25, 2026).
- Confirm the continued role of Ashoo Gupta as Vice President, Finance and Controller.
- Review Mr. Humer's prior experience as CFO at Foghorn Therapeutics and Viridian Therapeutics.
- Note that this filing does not update the company's financial position or operational outlook.